▎Edited by the WuXi AppTec content team

Recently, Parvus Therapeutics announced a global exclusive license collaboration and option agreement with AbbVie.Using Navacim from Parvus TherapeuticsRegulatory T cells (Treg)Immune Tolerance Platform Technology Develops and Commercializes Novel Therapies for Inflammatory Bowel Disease (IBD). This collaboration combines AbbVie's expertise in immunology with Parvus Therapeutics' innovative immune tolerance platform technology.

Navacims present multivalent peptide-major histocompatibility complex (peptide-MHCs) to T cells, thereby inducing endogenous expansion and differentiation of T cells into antigen-specific Tregs.sBy restoring organ-specific immune tolerance without compromising normal immune responses, this approach is under evaluation as a potential method to prevent or treat autoimmune diseases.

Parvus Therapeutics is a preclinical-stage company dedicated to developing its proprietary novel Navacim platform technology, which has the potential to treat or even cure autoimmune diseases.Parvus Therapeutics' lead candidate drug, PVT201, has demonstrated disease-modifying and liver-protective effects in preclinical models of primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis.Parvus Therapeutics Inc. throughNavacim Platform DevelopmentThe pipeline covers projects targeting IBD, Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, prevention of transplant rejection, and Celiac Disease.

According to the terms of the agreement, AbbVie will obtain through the collaborationNavacim PlatformDeveloped byIBD TherapyDevelopment and CommercializationGlobal Exclusive Option。Parvus Therapeutics Inc. will receive an upfront payment and potential investment, and is eligible for future development and commercial milestone payments.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.